Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and Freiermuth as they evaluate this new landscape from both the hematology and emergency medicine points of view.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Biree Andemariam, MD
Professor of Medicine
Division of Hematology/Oncology
Director, New England Sickle Cell Institute
Director, Connecticut Bleeding Disorders Center
University of Connecticut Health
Consulting Fees: Accordant, Afimmune, Agios, Bluebird Bio, Emmaus, Forma Therapeutics, GlaxoSmithKline, Global Blood Therapeutics, Hemanext, Novartis, NovoNordisk, Sanofi Genzyme, Vertex
Research: American Society of Hematology, Connecticut Department of Public Health, Forma Therapeutics, Global Blood Therapeutics, Hemanext, HRSA, Novartis, PCORI
Caroline E. Freiermuth, MD
Associate Professor of Emergency Medicine
University of Cincinnati
Consulting Fees: CSL Behring
- Jennifer Brutsche has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Barry Fiedel has nothing to disclose.
- Keith Johnson has nothing to disclose.
- Tim Person has nothing to disclose.
- Mara Siegel has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Recognize the lifelong physical and psychosocial burden that the various genotypes of sickle cell disease (SCD) impose on patients and their caregivers
- Formulate a comprehensive, evidence-based approach to treating SCD at all degrees of severity using current and emerging therapies in appropriately selected patients
- Discuss the common multi-organ comorbidities and complications associated with SCD
- Develop an interdisciplinary strategy for managing SCD and its sequelae as patients transition through multiple care settings across the stages of life
This activity is designed to meet the educational needs of hematologists, emergency medicine specialists, and primary care physicians.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
This activity is supported by an independent educational grant from Vertex.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.